Immune Cell Engineering Market Analysis and Forecast to 2032: By Cell Type (T Cells, NK Cells, Dendritic Cells, Tumor Cells, Stem Cells, Others), Product (Consumables, Instruments, Software), Disease Indication (Cardiovascular Diseases, Respiratory Diseases, Infectious Diseases, Cancer, Neurological Diseases, Others), Application (Research Applications, Cell Therapy & Regenerative Medicine, Others), End User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institutes, Cell Banks, Others), and Region

The global Immune Cell Engineering Market size was approximately USD 2.19 billion in 2022 and it is anticipated to grow up to nearly USD 13.18 billion by 2032, at a CAGR of 18.7% during the forecast period.

The immune cell engineering market refers to the dynamic and rapidly evolving field within biotechnology that focuses on the manipulation and enhancement of immune cells to treat various diseases, particularly cancer. This innovative approach involves modifying the genetic makeup or functional properties of immune cells, such as T cells, to bolster their ability to recognize and eliminate targeted cells, including cancerous ones. With the advent of cutting-edge technologies like CRISPR-Cas9 and advancements in cell therapy, the immune cell engineering market holds great promise for developing personalized and highly effective treatments, ushering in a new era in the realm of immunotherapy.

Immune Cell Engineering Market Scope and Report Structure

Report Attribute Details
Market Size in 2022$2.19 bn
Market Size in 2032$13.18 bn
Growth Rate (2022-32)18.7%
Historic Period2016-2021
Forecast Period2023-2032
Base Year2022
Segments CoveredCell Type, Product, Disease Indication, Application, End User, and Region
Key CompaniesThermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza, Miltenyi Biotec, Takara Bio Inc., Sartoroius CellGenix GmbH, FUJIFILM Irvine Scientific, Agilent Technologies, Inc., Bio-Techne, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Charles River Laboratories, Creative Bioarray, Sartorius AG, Novogene Co, Ltd., AGC Biologics, Catalent, Inc., WuXi AppTec, Discovery Life Sciences
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments

Market Trends and Drivers

The immune cell engineering market is witnessing significant growth driven by a confluence of factors. Advances in gene editing technologies, such as CRISPR-Cas9, have revolutionized the precision and efficiency of modifying immune cells, enabling the development of novel therapeutic approaches. The rising prevalence of cancer and infectious diseases, coupled with an increasing demand for personalized medicine, has spurred the adoption of immune cell engineering for the development of targeted immunotherapies. Moreover, the growing understanding of the immune system’s role in various diseases and the continuous exploration of innovative cell-based therapies contribute to the expansion of the immune cell engineering market. As the field continues to evolve, collaborations between academia and industry, as well as strategic partnerships, are expected to play a crucial role in shaping the future landscape of immune cell engineering.

Market Restraints and Challenges

The immune cell engineering market, while promising in its potential to revolutionize therapeutic interventions, faces notable restraints and challenges. Regulatory hurdles and safety concerns associated with the genetic modification of immune cells pose significant barriers to market expansion. Additionally, the high costs and complexities involved in developing and manufacturing personalized cell therapies limit widespread accessibility. Furthermore, the evolving landscape of technologies and the need for standardization in cell engineering processes present ongoing challenges for industry players. Overcoming these obstacles requires concerted efforts in research, development, and regulatory collaboration to ensure the safe and efficient deployment of immune cell engineering solutions in the realm of healthcare.

Immune Cell Engineering Market Segmental Overview

The report analyses the Immune Cell Engineering Market based on Cell Type, Product, Disease Indication, Application, End User, and Region

Immune Cell Engineering Market by  Cell Type

On the basis of cell type, the Immune Cell Engineering Market is segmented into T Cells, NK Cells, Dendritic Cells, Tumor Cells, Stem Cells, and Others. T cells, a subtype of lymphocytes, play a central role in orchestrating the immune response by recognizing and eliminating infected or aberrant cells. Harnessing the power of T cells for therapeutic purposes, particularly in the realm of adoptive cell therapies, has propelled the immune cell engineering market forward. The advent of technologies like chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of various cancers, marking a paradigm shift in personalized medicine. As research continues to uncover novel strategies for enhancing T cell functionality and specificity, the T cell segment stands as a cornerstone in shaping the future of immune cell engineering, offering promise for addressing diverse medical challenges through innovative immunotherapies.

Immune Cell Engineering Market by  Product

On the basis of Product, the Immune Cell Engineering Market is segmented into Consumables, Instruments, Software, and Others. The consumables segment is experiencing robust growth within the Market. As advancements in cell-based therapies gain momentum, there has been a surge in the consumption of essential consumables, such as culture media, reagents, and other supporting materials crucial for immune cell engineering processes. This uptick in demand can be attributed to the expanding applications of immune cell therapies in treating various diseases, including cancer and autoimmune disorders. The consumables segment’s robust growth underscores the pivotal role these materials play in facilitating the development and production of engineered immune cells, thereby contributing substantially to the overall expansion of the immune cell engineering market.

Immune Cell Engineering Market by Disease Indication

On the basis of  Disease Indication, the Immune Cell Engineering Market is segmented into Cardiovascular Diseases, Respiratory Diseases, Infectious Diseases, Cancer, Neurological Diseases, and Others. The Respiratory Diseases segment is experiencing robust growth within the Market, as respiratory ailments continue to pose a global health challenge, the demand for innovative therapeutic approaches, including immune cell engineering, has intensified. The advent of advanced technologies in this field, such as CRISPR-Cas9 gene editing and CAR-T cell therapies, holds immense promise for addressing respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and infectious respiratory diseases. The heightened emphasis on personalized medicine and precision therapies for respiratory disorders has further accelerated the growth of the immune cell engineering market, fostering a new era of targeted and efficient treatment modalities.

Immune Cell Engineering Market by Application

On the basis of  application the Immune Cell Engineering Market is segmented into Research Applications, Cell Therapy & Regenerative Medicine, and Others. Among these, in 2022, the Research Applications segment has exhibited robust growth, driven by the escalating demand for cutting-edge technologies and tools to advance immunology research. Researchers are increasingly leveraging immune cell engineering techniques to explore novel therapeutic avenues and gain insights into complex immunological processes. The expanding scope of applications, such as investigating immune responses, developing innovative cancer immunotherapies, and understanding autoimmune diseases, has fueled the adoption of immune cell engineering tools in research settings. The continuous pursuit of groundbreaking discoveries in immunology, coupled with advancements in gene editing technologies, positions the Research Applications segment as a pivotal contributor to the overall expansion of the immune cell engineering market.

Immune Cell Engineering Market by End-user

On the basis of  End-user, the Immune Cell Engineering Market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institutes, Cell Banks, and Others. Among these, in 2022, The Pharmaceutical and Biotechnology segments are witnessing substantial growth as end-users increasingly recognize the transformative potential of advanced therapies. With a surge in research and development activities aimed at enhancing immunotherapies, these industries are driving innovation in immune cell engineering techniques. The demand for personalized and precision medicine is fueling investments in genetic modification technologies and cell-based therapies, fostering a collaborative ecosystem between pharmaceutical and biotechnology companies. This synergy is propelling the development of novel immune cell engineering solutions, contributing significantly to the overall expansion of the market. As these sectors continue to prioritize advancements in immunotherapy, the immune cell engineering market is poised for continuous growth, with the promise of delivering groundbreaking treatments for various diseases.

Geographical Analysis of Immune Cell Engineering Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. In 2022, North America region has witnessed remarkable growth, driven by advancements in biotechnology and a surge in research and development activities. The region’s well-established healthcare infrastructure, coupled with a significant investment in cutting-edge technologies, has propelled the expansion of immune cell engineering applications. Increasing awareness of personalized medicine and the rising prevalence of chronic diseases have further fueled the demand for innovative immunotherapies. Additionally, collaborations between industry players and academic institutions have facilitated the development of novel immune cell engineering techniques, positioning North America at the forefront of this rapidly evolving market. As a result, the region is witnessing a substantial increase in the adoption of immune cell engineering solutions, creating a fertile ground for market expansion and driving the quest for more effective and targeted therapeutic interventions.

Major Players in the Immune Cell Engineering Market

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the Immune Cell Engineering Market include Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza, Miltenyi Biotec, Takara Bio Inc., Sartoroius CellGenix GmbH, FUJIFILM Irvine Scientific, Agilent Technologies, Inc., Bio-Techne, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Charles River Laboratories, Creative Bioarray, Sartorius AG, Novogene Co, Ltd., AGC Biologics, Catalent, Inc., WuXi AppTec, Discovery Life Sciences, among others.

COVID-19 Impact

he COVID-19 pandemic has significantly influenced the Immune Cell Engineering Market, both in terms of challenges and opportunities. On one hand, the increased focus on developing immunotherapies and vaccines to combat the virus has accelerated innovation and investment in immune cell engineering technologies. On the other hand, disruptions in the global supply chain, delays in clinical trials, and shifting priorities have posed obstacles for market players. The heightened awareness of the critical role of the immune system in fighting infectious diseases has underscored the importance of immune cell engineering, offering long-term growth potential as the industry adapts to the evolving landscape of pandemic-driven changes.

Recent Developments

  • In August 10, 2023, Astellas Pharma, Inc., a pharmaceutical company and Poseida Therapeutics, a clinical stage company entered into a strategic investment agreement to further support the development of cell therapies for cancer. Astellas will be investing a total of US$ 50 million and a one-time US$ 25 million payment for a right of exclusive negotiation and first refusal to license one of Poseida’s clinical-stage programs, P-MUC1C-ALLO1, which is an allogeneic chimeric antigen T cell (CAR-T) cell therapy in development for multiple solid tumor indications.
  • In July 19, 2023, Integrated Biosciences, a biotechnology company, announced a drug discovery platform that enables precise control of the integrated stress response (ISR), a biological pathway that is activated by cells in response to a wide variety of pathological and aging-associated conditions, to use synthetic biology, and in particular ontogenetic, to control age-related cellular signaling pathways. This technology allows for novel drug discovery efforts, allowing us to query specific aspects of cellular biology that produce faster, on-target drug screens with built-in mechanism of action validation.
  • In December 2022, Ferring B.V., a biopharmaceutical company, announced that the U.S. Food and Drug Administration had approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
  • In April 2022, Thermo Fisher Scientific, Inc., a biotechnology company, launched the new Gibco CTS DynaCellect Electroporation System for more consistent and efficient delivery of molecules into hard-to-transfect cells. This improved cell engineering workflow efficiency in cell line development and cell therapy manufacturing.
  • In December 2021, Novartis, a pharmaceutical company, announced the launch of T-Charge, its next-generation CAR-T platform, which can be used as the foundation for various new investigational CAR-T cell therapies in the company’s pipeline. The T-Charge platform helps in developing CAR-T cell therapy products with greater proliferative potential and fewer exhausted T cells.
  • In March 2021, Beckman Coulter, a biotechnology company, launched the CytoFLEX SRT cell sorter to automate and standardize sorting during cell engineering processes for reproducibility.

Immune Cell Engineering Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Immune Cell Engineering Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of Immune Cell Engineering Market in terms of revenue ($Million).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Dry Room Dehumidifier Industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country market analysis is also presented in this report.
  • Analytical depiction of the Immune Cell Engineering Market along with the current trends and future estimations to depict imminent investment pockets. The overall Dry Room Dehumidifier industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Immune Cell Engineering Market are also analyzed.

Frequently Asked Questions

Q1. How big is the Immune Cell Engineering Market?

Ans: The global Immune Cell Engineering Market size was approximately USD 2.19 billion in 2022 and it is anticipated to grow up to nearly USD 13.18 billion by 2032, at a CAGR of 18.7% during the forecast period..

Q2. What is the Immune Cell Engineering Market growth rate?

Ans. The growth rate of the Immune Cell Engineering Market is 7.2%

Q3. Which region holds a major market share for the market?

Ans. North America holds a major market share of the Immune Cell Engineering Market in 2022.

Q4. Which segment accounted for the largest Immune Cell Engineering Market share?

Ans. By application, the Research Applications segment accounted for the largest Immune Cell Engineering Market share in 2022.

Q5. Who are the key players in the Immune Cell Engineering Market?

Ans. The Immune Cell Engineering Market report includes players such as Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza, Miltenyi Biotec, Takara Bio Inc., Sartoroius CellGenix GmbH, FUJIFILM Irvine Scientific, Agilent Technologies, Inc., Bio-Techne, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Charles River Laboratories, Creative Bioarray, Sartorius AG, Novogene Co, Ltd., AGC Biologics, Catalent, Inc., WuXi AppTec, Discovery Life Sciences, among others.

Q6. What is the factor driving the Immune Cell Engineering Market growth?

Ans. The major factor driving the growth of the market is the increasing investments in cell-based research

Q7. What are the key growth strategies of Immune Cell Engineering Market players?

Ans. The key growth strategies of Immune Cell Engineering Market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the Immune Cell Engineering Market during the forecast period?

Ans. The North America region will provide more business opportunities for the Immune Cell Engineering Market during the forecast period.

Table of Contents

Chapter 1. Immune Cell Engineering Market Overview
1.1. Objectives of the Study
1.2. Market Definition and Scope of the Report
1.3. Report Limitations
1.4. Years & Currency Considered in the Study
1.5. Research Methodologies
1.5.1. Secondary Research
1.5.1.1. Data Collection
1.5.1.2. List of Secondary Sources
1.5.1.3. Key Data from Secondary Sources
1.5.2. Primary Research
1.5.2.1. List of Primary Research Sources
1.5.3. Market Product Estimation: Top-Down Approach
1.5.4. Market Product Estimation: Bottom-Up Approach
1.5.5. Data Triangulation and Validation

Chapter 2. Executive Summary
2.1. Summary
2.2. Key Highlights of the Market
2.3. Analyst’s Review

Chapter 3. Premium Insights on the Market
3.1. Market Attractiveness Analysis, by Region
3.2. Market Attractiveness Analysis, by Cell Type
3.3. Market Attractiveness Analysis, by Product
3.4. Market Attractiveness Analysis, by Disease Indication
3.5. Market Attractiveness Analysis, by Application
3.6. Market Attractiveness Analysis, by End-user

Chapter 4. Immune Cell Engineering Market Outlook
4.1. Immune Cell Engineering Market Segmentation
4.2. Market Dynamics
4.2.1. Market Drivers
4.2.1.1. Driver 1
4.2.1.2. Driver 2
4.2.1.3. Driver 3
4.2.2. Market Restraints
4.2.2.1. Restraint 1
4.2.2.2. Restraint 2
4.2.3. Market Opportunities
4.2.3.1. Opportunity 1
4.2.3.2. Opportunity 2
4.3. Porter’s Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Buyers
4.3.4. Bargaining Power of Supplier
4.3.5. Competitive Rivalry
4.4. PESTLE Analysis
4.5. Value Chain Analysis
4.6. Impact of COVID-19 on the Immune Cell Engineering Market
4.7. Impact of the Russia and Ukraine War on the Immune Cell Engineering Market
4.8. Parent Market Analysis
4.9. Immune Cell Engineering Ecosystem Analysis
4.10. Case Study Analysis
4.11. Pricing Analysis
4.12. Regulatory Landscape
4.13. Patent Analysis
4.14. Disease Indication Trend Analysis

Chapter 5. Immune Cell Engineering Market, by Cell Type
5.1. Market Overview
5.2. T Cells
5.2.1. Key Market Trends & Opportunity Analysis
5.2.2. Market Product and Forecast, by Region
5.3. NK Cells
5.3.1. Key Market Trends & Opportunity Analysis
5.3.2. Market Product and Forecast, by Region
5.4. Dendritic Cells
5.4.1. Key Market Trends & Opportunity Analysis
5.4.2. Market Product and Forecast, by Region
5.5. Tumor Cells
5.5.1. Key Market Trends & Opportunity Analysis
5.5.2. Market Product and Forecast, by Region
5.6. Stem Cells
5.6.1. Key Market Trends & Opportunity Analysis
5.6.2. Market Product and Forecast, by Region
5.7. Others
5.7.1. Key Market Trends & Opportunity Analysis
5.7.2. Market Product and Forecast, by Region

Chapter 6. Immune Cell Engineering Market, by Product
6.1. Market Overview
6.2. Consumables
6.2.1. Key Market Trends & Opportunity Analysis
6.2.2. Market Product and Forecast, by Region
6.3. Instruments
6.3.1. Key Market Trends & Opportunity Analysis
6.3.2. Market Product and Forecast, by Region
6.4. Software
6.4.1. Key Market Trends & Opportunity Analysis
6.4.2. Market Product and Forecast, by Region

Chapter 7. Immune Cell Engineering Market, by Disease Indication
7.1. Market Overview
7.2. Cardiovascular Diseases
7.2.1. Key Market Trends & Opportunity Analysis
7.2.2. Market Product and Forecast, by Region
7.3. Respiratory Diseases
7.3.1. Key Market Trends & Opportunity Analysis
7.3.2. Market Product and Forecast, by Region
7.4. Infectious Diseases
7.4.1. Key Market Trends & Opportunity Analysis
7.4.2. Market Product and Forecast, by Region
7.5. Cancer
7.5.1. Key Market Trends & Opportunity Analysis
7.5.2. Market Product and Forecast, by Region
7.6. Neurological Diseases
7.6.1. Key Market Trends & Opportunity Analysis
7.6.2. Market Product and Forecast, by Region
7.7. Others
7.7.1. Key Market Trends & Opportunity Analysis
7.7.2. Market Product and Forecast, by Region

Chapter 8. Immune Cell Engineering Market, by Application
8.1. Market Overview
8.2. Research Applications
8.2.1. Key Market Trends & Opportunity Analysis
8.2.2. Market Product and Forecast, by Region
8.3. Cell Therapy & Regenerative Medicine
8.3.1. Key Market Trends & Opportunity Analysis
8.3.2. Market Product and Forecast, by Region
8.4. Others
8.4.1. Key Market Trends & Opportunity Analysis
8.4.2. Market Product and Forecast, by Region

Chapter 9. Immune Cell Engineering Market, by End-user
9.1. Market Overview
9.2. Pharmaceutical & Biotechnology Companies
9.2.1. Key Market Trends & Opportunity Analysis
9.2.2. Market Product and Forecast, by Region
9.3. Hospitals & Clinics
9.3.1. Key Market Trends & Opportunity Analysis
9.3.2. Market Product and Forecast, by Region
9.4. Academic & Research Institutes
9.4.1. Key Market Trends & Opportunity Analysis
9.4.2. Market Product and Forecast, by Region
9.5. Cell Banks
9.5.1. Key Market Trends & Opportunity Analysis
9.5.2. Market Product and Forecast, by Region
9.6. Others
9.6.1. Key Market Trends & Opportunity Analysis
9.6.2. Market Product and Forecast, by Region

Chapter 10. Immune Cell Engineering Market, by Region
10.1. Overview
10.2. North America
10.2.1. Key Market Trends and Opportunities
10.2.2. North America Immune Cell Engineering Market Product and Forecast, by Cell Type
10.2.3. North America Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.2.4. North America Immune Cell Engineering Market Product and Forecast, by Product
10.2.5. North America Immune Cell Engineering Market Product and Forecast, by Application
10.2.6. North America Immune Cell Engineering Market Product and Forecast, by End-user
10.2.7. The U.S.
10.2.7.1. The U.S. Immune Cell Engineering Market Product and Forecast, by Cell Type
10.2.7.2. The U.S. Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.2.7.3. The U.S. Immune Cell Engineering Market Product and Forecast, by Product
10.2.7.4. The U.S. Immune Cell Engineering Market Product and Forecast, by Application
10.2.7.5. The U.S. Immune Cell Engineering Market Product and Forecast, by End-user
10.2.8. Canada
10.2.8.1. Canada Immune Cell Engineering Market Product and Forecast, by Cell Type
10.2.8.2. Canada Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.2.8.3. Canada Immune Cell Engineering Market Product and Forecast, by Product
10.2.8.4. Canada Immune Cell Engineering Market Product and Forecast, by Application
10.2.8.5. Canada Immune Cell Engineering Market Product and Forecast, by End-user
10.2.9. Mexico
10.2.9.1. Mexico Immune Cell Engineering Market Product and Forecast, by Cell Type
10.2.9.2. Mexico Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.2.9.3. Mexico Immune Cell Engineering Market Product and Forecast, by Product
10.2.9.4. Mexico Immune Cell Engineering Market Product and Forecast, by Application
10.2.9.5. Mexico Immune Cell Engineering Market Product and Forecast, by End-user
10.3. Europe
10.3.1. Key Market Trends and Opportunities
10.3.2. Europe Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.3. Europe Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.4. Europe Immune Cell Engineering Market Product and Forecast, by Product
10.3.5. Europe Immune Cell Engineering Market Product and Forecast, by Application
10.3.6. Europe Immune Cell Engineering Market Product and Forecast, by End-user
10.3.7. Europe Immune Cell Engineering Market Product and Forecast, by Country
10.3.8. The UK
10.3.8.1. The UK Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.8.2. The UK Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.8.3. The UK Immune Cell Engineering Market Product and Forecast, by Product
10.3.8.4. The UK Immune Cell Engineering Market Product and Forecast, by Application
10.3.8.5. The UK Immune Cell Engineering Market Product and Forecast, by End-user
10.3.9. Germany
10.3.9.1. Germany Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.9.2. Germany Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.9.3. Germany Immune Cell Engineering Market Product and Forecast, by Product
10.3.9.4. Germany Immune Cell Engineering Market Product and Forecast, by Application
10.3.9.5. Germany Immune Cell Engineering Market Product and Forecast, by End-user
10.3.10. France
10.3.10.1. France Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.10.2. France Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.10.3. France Immune Cell Engineering Market Product and Forecast, by Product
10.3.10.4. France Immune Cell Engineering Market Product and Forecast, by Application
10.3.10.5. France Immune Cell Engineering Market Product and Forecast, by End-user
10.3.11. Spain
10.3.11.1. Spain Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.11.2. Spain Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.11.3. Spain Immune Cell Engineering Market Product and Forecast, by Product
10.3.11.4. Spain Immune Cell Engineering Market Product and Forecast, by Application
10.3.11.5. Spain Immune Cell Engineering Market Product and Forecast, by End-user
10.3.12. Italy
10.3.12.1. Italy Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.12.2. Italy Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.12.3. Italy Immune Cell Engineering Market Product and Forecast, by Product
10.3.12.4. Italy Immune Cell Engineering Market Product and Forecast, by Application
10.3.12.5. Italy Immune Cell Engineering Market Product and Forecast, by End-user
10.3.13. Netherlands
10.3.13.1. Netherlands Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.13.2. Netherlands Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.13.3. Netherlands Immune Cell Engineering Market Product and Forecast, by Product
10.3.13.4. Netherlands Immune Cell Engineering Market Product and Forecast, by Application
10.3.13.5. Netherland Immune Cell Engineering Market Product and Forecast, by End-user
10.3.14. Sweden
10.3.14.1. Sweden Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.14.2. Sweden Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.14.3. Sweden Immune Cell Engineering Market Product and Forecast, by Product
10.3.14.4. Sweden Immune Cell Engineering Market Product and Forecast, by Application
10.3.14.5. Sweden Immune Cell Engineering Market Product and Forecast, by End-user
10.3.15. Switzerland
10.3.15.1. Switzerland Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.15.2. Switzerland Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.15.3. Switzerland Immune Cell Engineering Market Product and Forecast, by Product
10.3.15.4. Switzerland Immune Cell Engineering Market Product and Forecast, by Application
10.3.15.5. Switzerland Immune Cell Engineering Market Product and Forecast, by End-user
10.3.16. Denmark
10.3.16.1. Denmark Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.16.2. Denmark Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.16.3. Denmark Immune Cell Engineering Market Product and Forecast, by Product
10.3.16.4. Denmark Immune Cell Engineering Market Product and Forecast, by Application
10.3.16.5. Denmark Immune Cell Engineering Market Product and Forecast, by End-user
10.3.17. Finland
10.3.17.1. Finland Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.17.2. Finland Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.17.3. Finland Immune Cell Engineering Market Product and Forecast, by Product
10.3.17.4. Finland Immune Cell Engineering Market Product and Forecast, by Application
10.3.17.5. Finland Immune Cell Engineering Market Product and Forecast, by End-user
10.3.18. Russia
10.3.18.1. Russia Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.18.2. Russia Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.18.3. Russia Immune Cell Engineering Market Product and Forecast, by Product
10.3.18.4. Russia Immune Cell Engineering Market Product and Forecast, by Application
10.3.18.5. Russia Immune Cell Engineering Market Product and Forecast, by End-user
10.3.19. Rest of Europe
10.3.19.1. Rest of Europe Immune Cell Engineering Market Product and Forecast, by Cell Type
10.3.19.2. Rest of Europe Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.3.19.3. Rest of Europe Immune Cell Engineering Market Product and Forecast, by Product
10.3.19.4. Rest of Europe Immune Cell Engineering Market Product and Forecast, by Application
10.3.19.5. Rest of Europe Immune Cell Engineering Market Product and Forecast, by End-user
10.4. Asia-Pacific
10.4.1. Key Market Trends and Opportunities
10.4.2. Asia-Pacific Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.3. Asia-Pacific Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.4. Asia-Pacific Immune Cell Engineering Market Product and Forecast, by Product
10.4.5. Asia-Pacific Immune Cell Engineering Market Product and Forecast, by Application
10.4.6. Asia-Pacific Immune Cell Engineering Market Product and Forecast, by End-user
10.4.7. Asia-Pacific Immune Cell Engineering Market Product and Forecast, by Country
10.4.8. China
10.4.8.1. China Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.8.2. China Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.8.3. China Immune Cell Engineering Market Product and Forecast, by Product
10.4.8.4. China Immune Cell Engineering Market Product and Forecast, by Application
10.4.8.5. China Immune Cell Engineering Market Product and Forecast, by End-user
10.4.9. India
10.4.9.1. India Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.9.2. India Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.9.3. India Immune Cell Engineering Market Product and Forecast, by Product
10.4.9.4. India Immune Cell Engineering Market Product and Forecast, by Application
10.4.9.5. India Immune Cell Engineering Market Product and Forecast, by End-user
10.4.10. Japan
10.4.10.1. Japan Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.10.2. Japan Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.10.3. Japan Immune Cell Engineering Market Product and Forecast, by Product
10.4.10.4. Japan Immune Cell Engineering Market Product and Forecast, by Application
10.4.10.5. Japan Immune Cell Engineering Market Product and Forecast, by End-user
10.4.11. South Korea
10.4.11.1. South Korea Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.11.2. South Korea Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.11.3. South Korea Immune Cell Engineering Market Product and Forecast, by Product
10.4.11.4. South Korea Immune Cell Engineering Market Product and Forecast, by Application
10.4.11.5. South Korea Immune Cell Engineering Market Product and Forecast, by End-user
10.4.12. Australia
10.4.12.1. Australia Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.12.2. Australia Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.12.3. Australia Immune Cell Engineering Market Product and Forecast, by Product
10.4.12.4. Australia Immune Cell Engineering Market Product and Forecast, by Application
10.4.12.5. Australia Immune Cell Engineering Market Product and Forecast, by End-user
10.4.13. Singapore
10.4.13.1. Singapore Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.13.2. Singapore Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.13.3. Singapore Immune Cell Engineering Market Product and Forecast, by Product
10.4.13.4. Singapore Immune Cell Engineering Market Product and Forecast, by Application
10.4.13.5. Singapore Immune Cell Engineering Market Product and Forecast, by End-user
10.4.14. Indonesia
10.4.14.1. Indonesia Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.14.2. Indonesia Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.14.3. Indonesia Immune Cell Engineering Market Product and Forecast, by Product
10.4.14.4. Indonesia Immune Cell Engineering Market Product and Forecast, by Application
10.4.14.5. Indonesia Immune Cell Engineering Market Product and Forecast, by End-User
10.4.15. Taiwan
10.4.15.1. Taiwan Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.15.2. Taiwan Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.15.3. Taiwan Immune Cell Engineering Market Product and Forecast, by Product
10.4.15.4. Taiwan Immune Cell Engineering Market Product and Forecast, by Application
10.4.15.5. Taiwan Immune Cell Engineering Market Product and Forecast, by End-user
10.4.16. Malaysia
10.4.16.1. Malaysia Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.16.2. Malaysia Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.16.3. Malaysia Immune Cell Engineering Market Product and Forecast, by Product
10.4.16.4. Malaysia Immune Cell Engineering Market Product and Forecast, by Application
10.4.16.5. Malaysia Immune Cell Engineering Market Product and Forecast, by End-user
10.4.17. Rest of Asia-Pacific
10.4.17.1. Rest of Asia-Pacific Immune Cell Engineering Market Product and Forecast, by Cell Type
10.4.17.2. Rest of Asia-Pacific Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.4.17.3. Rest of Asia-Pacific Immune Cell Engineering Market Product and Forecast, by Product
10.4.17.4. Rest of Asia-Pacific Immune Cell Engineering Market Product and Forecast, by Application
10.4.17.5. Rest of Asia-Pacific Immune Cell Engineering Market Product and Forecast, by End-user
10.5. Rest of the World
10.5.1. Key Market Trends and Opportunities
10.5.2. Rest of the World Immune Cell Engineering Market Product and Forecast, by Cell Type
10.5.3. Rest of the World Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.5.4. Rest of the World Immune Cell Engineering Market Product and Forecast, by Product
10.5.5. Rest of the World Immune Cell Engineering Market Product and Forecast, by Application
10.5.6. Rest of the World Immune Cell Engineering Market Product and Forecast, by End-user
10.5.7. Rest of the World Immune Cell Engineering Market Product and Forecast, by Country
10.5.8. Latin America
10.5.8.1. Latin America Immune Cell Engineering Market Product and Forecast, by Cell Type
10.5.8.2. Latin America Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.5.8.3. Latin America Immune Cell Engineering Market Product and Forecast, by Product
10.5.8.4. Latin America Immune Cell Engineering Market Product and Forecast, by Application
10.5.8.5. Latin America Immune Cell Engineering Market Product and Forecast, by End-user
10.5.9. Middle East
10.5.9.1. Middle East Immune Cell Engineering Market Product and Forecast, by Cell Type
10.5.9.2. Middle East Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.5.9.3. Middle East Immune Cell Engineering Market Product and Forecast, by Product
10.5.9.4. Middle East Immune Cell Engineering Market Product and Forecast, by Application
10.5.9.5. Middle East Immune Cell Engineering Market Product and Forecast, by End-user
10.5.10. Africa
10.5.10.1. Africa Immune Cell Engineering Market Product and Forecast, by Cell Type
10.5.10.2. Africa Immune Cell Engineering Market Product and Forecast, by Disease Indication
10.5.10.3. Africa Immune Cell Engineering Market Product and Forecast, by Product
10.5.10.4. Africa Immune Cell Engineering Market Product and Forecast, by Application
10.5.10.5. Africa Immune Cell Engineering Market Product and Forecast, by End-user

Chapter 11. Competitive Landscape
11.1. Overview
11.2. Market Share Analysis/Key Player Positioning
11.3. Competitive Leadership Mapping
11.3.1. Star Players
11.3.2. Innovators
11.3.3. Emerging Players
11.4. Vendor Benchmarking
11.5. Developmental Strategy Benchmarking
11.5.1. New Product Developments
11.5.2. Product Launches
11.5.3. Business Expansions
11.5.4. Partnerships, Joint Ventures, and Collaborations
11.5.5. Mergers and Acquisitions

Chapter 12. Company Profiles
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Company Snapshot
12.1.3. Business Segments
12.1.4. Business Performance
12.1.5. Product offerings
12.1.6. Key Developmental Strategies
12.1.7. SWOT Analysis
12.2. Thermo Fisher Scientific Inc.
12.2.1. Company Overview
12.2.2. Company Snapshot
12.2.3. Business Segments
12.2.4. Business Performance
12.2.5. Product offerings
12.2.6. Key Developmental Strategies
12.2.7. SWOT Analysis
12.3. Merck KGaA
12.3.1. Company Overview
12.3.2. Company Snapshot
12.3.3. Business Segments
12.3.4. Business Performance
12.3.5. Product offerings
12.3.6. Key Developmental Strategies
12.3.7. SWOT Analysis
12.4. Danaher Corporation
12.4.1. Company Overview
12.4.2. Company Snapshot
12.4.3. Business Segments
12.4.4. Business Performance
12.4.5. Product offerings
12.4.6. Key Developmental Strategies
12.4.7. SWOT Analysis
12.5. Lonza
12.5.1. Company Overview
12.5.2. Company Snapshot
12.5.3. Business Segments
12.5.4. Business Performance
12.5.5. Product offerings
12.5.6. Key Developmental Strategies
12.5.7. SWOT Analysis
12.6. Miltenyi Biotec
12.6.1. Company Overview
12.6.2. Company Snapshot
12.6.3. Business Segments
12.6.4. Business Performance
12.6.5. Product offerings
12.6.6. Key Developmental Strategies
12.6.7. SWOT Analysis
12.7. Takara Bio Inc.
12.7.1. Company Overview
12.7.2. Company Snapshot
12.7.3. Business Segments
12.7.4. Business Performance
12.7.5. Product offerings
12.7.6. Key Developmental Strategies
12.7.7. SWOT Analysis
12.8. Sartoroius CellGenix GmbH
12.8.1. Company Overview
12.8.2. Company Snapshot
12.8.3. Business Segments
12.8.4. Business Performance
12.8.5. Product offerings
12.8.6. Key Developmental Strategies
12.8.7. SWOT Analysis
12.9. FUJIFILM Irvine Scientific
12.9.1. Company Overview
12.9.2. Company Snapshot
12.9.3. Business Segments
12.9.4. Business Performance
12.9.5. Product offerings
12.9.6. Key Developmental Strategies
12.9.7. SWOT Analysis
12.10. Agilent Technologies, Inc.
12.10.1. Company Overview
12.10.2. Company Snapshot
12.10.3. Business Segments
12.10.4. Business Performance
12.10.5. Product offerings
12.10.6. Key Developmental Strategies
12.10.7. SWOT Analysis
12.11. Bio-Techne
12.11.1. Company Overview
12.11.2. Company Snapshot
12.11.3. Business Segments
12.11.4. Business Performance
12.11.5. Product offerings
12.11.6. Key Developmental Strategies
12.11.7. SWOT Analysis
12.12. Bio-Rad Laboratories, Inc.
12.12.1. Company Overview
12.12.2. Company Snapshot
12.12.3. Business Segments
12.12.4. Business Performance
12.12.5. Product offerings
12.12.6. Key Developmental Strategies
12.12.7. SWOT Analysis
12.13. Becton, Dickinson and Company
12.13.1. Company Overview
12.13.2. Company Snapshot
12.13.3. Business Segments
12.13.4. Business Performance
12.13.5. Product offerings
12.13.6. Key Developmental Strategies
12.13.7. SWOT Analysis
12.14. Charles River Laboratories
12.14.1. Company Overview
12.14.2. Company Snapshot
12.14.3. Business Segments
12.14.4. Business Performance
12.14.5. Product offerings
12.14.6. Key Developmental Strategies
12.14.7. SWOT Analysis
12.15. Creative Bioarray
12.15.1. Company Overview
12.15.2. Company Snapshot
12.15.3. Business Segments
12.15.4. Business Performance
12.15.5. Product offerings
12.15.6. Key Developmental Strategies
12.15.7. SWOT Analysis
12.16. Sartorius AG
12.16.1. Company Overview
12.16.2. Company Snapshot
12.16.3. Business Segments
12.16.4. Business Performance
12.16.5. Product offerings
12.16.6. Key Developmental Strategies
12.16.7. SWOT Analysis
12.17. Novogene Co, Ltd.
12.17.1. Company Overview
12.17.2. Company Snapshot
12.17.3. Business Segments
12.17.4. Business Performance
12.17.5. Product offerings
12.17.6. Key Developmental Strategies
12.17.7. SWOT Analysis
12.18. AGC Biologics
12.18.1. Company Overview
12.18.2. Company Snapshot
12.18.3. Business Segments
12.18.4. Business Performance
12.18.5. Product offerings
12.18.6. Key Developmental Strategies
12.18.7. SWOT Analysis
12.19. Catalent, Inc
12.19.1. Company Overview
12.19.2. Company Snapshot
12.19.3. Business Segments
12.19.4. Business Performance
12.19.5. Product offerings
12.19.6. Key Developmental Strategies
12.19.7. SWOT Analysis
12.20. WuXi AppTec
12.20.1. Company Overview
12.20.2. Company Snapshot
12.20.3. Business Segments
12.20.4. Business Performance
12.20.5. Product offerings
12.20.6. Key Developmental Strategies
12.20.7. SWOT Analysis
12.21. Discovery Life Sciences
12.21.1. Company Overview
12.21.2. Company Snapshot
12.21.3. Business Segments
12.21.4. Business Performance
12.21.5. Product offerings
12.21.6. Key Developmental Strategies
12.21.7. SWOT Analysis
*The list of companies is subject to change during the final compilation of the report

Key Players
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Lonza
  • Miltenyi Biotec
  • Takara Bio Inc.
  • Sartoroius CellGenix GmbH
  • FUJIFILM Irvine Scientific
  • Agilent Technologies, Inc.
  • Bio-Techne
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company
  • Charles River Laboratories
  • Creative Bioarray
  • Sartorius AG
  • Novogene Co, Ltd.
  • AGC Biologics
  • Catalent, Inc
  • WuXi AppTec
  • Discovery Life Sciences
Market Segmentation

By Cell Type

  • T Cells
  • NK Cells
  • Dendritic Cells
  • Tumor Cells
  • Stem Cells
  • Others

By Product

  • Consumables
  • Instruments
  • Software

By Disease Indication

  • Cardiovascular Diseases
  • Respiratory Diseases
  • Infectious Diseases
  • Cancer
  • Neurological Diseases
  • Others

By Application

  • Research Applications
  • Cell Therapy & Regenerative Medicine
  • Others

By End User

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinics
  • Academic & Research Institutes
  • Cell Banks
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    • Rest of Europe
  • The Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

Enteric disease testing is a diagnostic tool used…
Synthetic biology is the design and construction of…
Pharmaceutical Contract Development and Manufacturing (CDMO) is a…
Transient protein expression is a process by which…
The Nutricosmetics market size was over USD 7.23…
Lipid Nanoparticles (LNPs) CDMO is a contract development…
The global Biopreservation Market was valued at USD…
Male Hypogonadism is characterized by a decrease in…
Keloid treatment is a medical procedure used to…
Dental laboratories are businesses that provide dental products…